Compare · ABT vs RPRX
ABT vs RPRX
Side-by-side comparison of Abbott Laboratories (ABT) and Royalty Pharma plc (RPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and RPRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $190.97B, about 5.4x RPRX ($35.31B).
- ABT has been more active in the news (11 items in the past 4 weeks vs 8 for RPRX).
- ABT has more recent analyst coverage (25 ratings vs 12 for RPRX).
- Company
- Abbott Laboratories
- Royalty Pharma plc
- Price
- -
- -
- Market cap
- $190.97B
- $35.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest ABT
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
Latest RPRX
- EVP & Chairman, Partnering Hite Christopher sold $5,997,250 worth of Class A Ordinary Shares (100,000 units at $59.97) as part of a pre-agreed trading plan and gifted 16,800 units of Class A Ordinary Shares, decreasing direct ownership by 42% to 23,200 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Royalty Pharma plc
- EVP & CFO Coyne Terrance P. sold $645,551 worth of Class A Ordinary Shares (11,002 units at $58.68) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 13F-NT filed by Royalty Pharma plc
- SEC Form 144 filed by Royalty Pharma plc
- SEC Form 144 filed by Royalty Pharma plc
- Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
- Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
- CEO, Chairman of the Board Legorreta Pablo G. was granted 65,216 units of Class A Ordinary Shares, increasing direct ownership by 5% to 1,307,820 units (SEC Form 4)
- EVP & CFO Coyne Terrance P. was granted 11,002 units of Class A Ordinary Shares (SEC Form 4)